Tempe, Ariz.-based Clinical Research Advantage (CRA), a wholly owned network of clinical trial sites, has expanded both its geographic and therapeutic reach by acquiring the late phase division of Comprehensive Clinical Development (CCD).
CRA said the acquisition will allow it to offer pharmaceutical sponsors and CROs an across-the-board solution for their diverse clinical research needs.
Founded in 1992, CRA includes 63 sites operating under CRA and Radiant Research. Both brands conduct stage II-IV clinical trials. CRA focuses on family practice and general medicine, while Radiant conducts multi-specialty and consumer trials. CRA acquired Radiant Research in 2012.
CCD conducts psychiatric clinical trials, specifically in schizophrenia, bipolar disorder, depression and Alzheimer’s disease. CCD has participated in the development of every major psychiatric drug that has been developed over the past 10 years.
“By adding Comprehensive Clinical Development to the CRA family of trial sites we are able to increase our capabilities to meet the needs of the growing pharmaceutical marketplace,” said Mark S. Hanley, chief executive officer of CRA. “We are excited about this partnership and the opportunity to move into new therapeutic areas of clinical research. CCD has an impressive track record in psychiatric trials, and we see it as an ideal partner as we continue to expand our operations.”
Based in Miramar, Fla., CCD was founded in 1998. It operates four independent sites in Atlanta, Ga., Cerritos, Calif., Holliswood, N.Y., and Washington, D.C. The combined companies will continue to function under the names CRA and CCD, but will be looking to integrate and streamline their operations where appropriate.